Search
forLearn
5 / 801 resultslearn DMSO
learn Vascular Endothelial Growth Factor
learn medium chain triglycerides
learn Greyverse
Research
5 / 54 results
research Use of smartphones in telemedicine: Comparative study between standard and teledermatological evaluation of high-complex care hospital inpatients
Low-cost videomicroscopes might not be reliable for examining scalp disorders compared to standard methods.
research A national survey of teledermatology education in United States residency programs
Low-cost videomicroscopes may not be reliable for diagnosing scalp disorders, smartphones could be reasonable for teledermatology, and U.S. residency programs need more teledermatology training.
research A Contemporary View on Felix Pinkus’ Concept of the Vitreous Membrane
The vitreous membrane in hair follicles changes shape during the hair cycle and may affect hair growth and nutrient exchange.
research Use of Low-Cost Videomicroscopy versus Standard Videodermatoscopy in Trichoscopy: A Controlled, Blinded Noninferiority Trial
Low-cost videomicroscopes are not as reliable as standard videodermatoscopes for scalp examination due to lower image quality.
research Screening and culture of human vaginal mucosa stem cells
Vaginal mucosa stem cells can be effectively isolated and cultured using specific methods.
Community Join
5 / 1000+ resultscommunity Topical VPA - Anyone experiences here?
The conversation is about using topical valproic acid (VPA) for hair loss, focusing on its application method, usage frequency, and combination with other treatments like micro-needling. No specific experiences with VPA were shared.
community I’m taking Veradermics VDPHL01 - AMA
A participant using Veradermics VDPHL01, an extended-release oral minoxidil, experienced significant hair regrowth from Norwood 6 to Norwood 3V without side effects. They plan to use dutasteride after the treatment to maintain results.
community Veradermics VDPHL01: why isn’t anyone talking about it?
Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.
community Following the recent IPO and the positive Phase 3 clinical data for VDPHL01 (extended-release oral minoxidil), what is the projected timeline for the FDA submission and the subsequent commercial availability on the market?
Veradermics' extended-release oral minoxidil is expected to be commercially available in 2027-2028, while another company, Minx, may release a similar product sooner. VDPHL01 is considered more clinically validated compared to Minx.
community Very exited about Veradermics,
Veradermics is a promising new treatment for hair loss, essentially a repackaged version of Minoxidil. The user is optimistic about its potential effectiveness.